Pasar al contenido principal

POTENCIAL DEL SISTEMA ENDOCANNABINOIDE FRENTE A MECANISMOS PATOGENICOS ASOCIADOS CON LA NEURODEGENERACION: ENFASIS EN LA REACTIVIDAD GLIAL Y LA AGREGACION PROTEICA

PID2021-128906OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

  • Silva-Llanes, Ignacio
  • Martín-Baquero, Raquel
  • Berrojo-Armisen, Alicia
  • Rodríguez-Cueto, Carmen
  • Fernández-Ruiz, Javier
  • Lago, Eva de
  • Lastres-Becker, Isabel
Frontotemporal dementia (FTD) causes progressive neurodegeneration in the frontal and temporal lobes, leading to behavioral, cognitive, and language impairments. With no effective treatment available, exploring new therapeutic approaches is critical. Recent research highlights the transcription factor Nuclear Factor erythroid-derived 2-like 2 (NRF2) as vital in limiting neurodegeneration, with its activation shown to mitigate FTD-related processes like inflammation. Dimethyl fumarate (DMF), an NRF2 activator, has demonstrated neuroprotective effects in a TAU-dependent FTD mouse model, reducing neurodegeneration and inflammation. This suggests DMF repositioning potential for FTD treatment. Until now, no trial had been conducted to analyze the effect of DMF on TDP-43-dependent FTD. In this study, we aimed to determine the potential therapeutic efficacy of DMF in a TDP-43-related FTD mouse model that exhibits early cognitive impairment. Mice received oral DMF treatment every other day from presymptomatic to symptomatic stages. By post-natal day (PND) 60, an improvement in cognitive function is already evident, becoming even more pronounced by PND90. This cognitive enhancement correlates with the neuroprotection observed in the dentate gyrus and a reduction in astrogliosis in the stratum lacunosum-moleculare zone. At the prefrontal cortex (PFC) level, a neuroprotective effect of DMF is also observed, accompanied by a reduction in astrogliosis. Collectively, our results suggest a potential therapeutic application of DMF for patients with TDP-43-dependent FTD., This work was supported MINECO (PID2019-105600RB-I00 and PID2022-137065OB-I00 to I.L.-B. and PID2021-128906OB-I00 to E.D.L./J.F.-R.) and ISCiii CIBERNED (CB06/05/0089 to I.L.-B./E.D.L./J.F.-R.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

  • Burgaz, Sonia
  • Navarro, Elisa
  • Rodríguez-Carreiro, Santiago
  • Navarrete, Carmen
  • Garrido-Rodríguez, Martín
  • Lastres-Becker, Isabel
  • Chocarro, Julia
  • Lanciego, José Luis
  • Muñoz, Eduardo
  • Fernández-Ruiz, Javier
This work has been supported by grants from CIBERNED (CB06/05/0089 to JF-R), MICINN (PID2021-128906OB-I00 to JF-R, PID2022-139936OA-I00 to EN and PID2022-137065OB-I00 to ILB) with FEDER funds and Michael J. Fox Foundation (MJFF-022552 to JF-R). These agencies had no further role in study design, the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. Sonia Burgaz was a predoctoral fellow supported by the Complutense University, whereas Santiago Rodríguez-Carreiro was supported by the Ministry of University (FPU Programme)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (−) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives

  • Rodríguez-Carreiro, S.
  • Gómez-Cañas, M.
  • Lubrini, F.
  • Gonzalo-Consuegra, C.
  • Winkler, M.
  • Caprioglio, D.
  • Appendino, G.
  • García, C.
  • Morales, Paula
  • Jagerovic, Nadine
  • Fischer, J. T.
  • Fiebich, B. L.
  • Goetz, M. R.
  • Muñoz, E.
Cannabidiol (CBD) and cannabidivarin (CBDV) have shown promising clinical efficacy for the management of epilepsy, and beneficial effects have been demonstrated for CBD in a diversity of other pathologies (pain, schizophrenia, Tourette syndrome, anxiety). However, the mechanism(s) involved are still largely elusive, as are the molecular target(s) involved. CBD and CBDV do not orthosterically bind the cannabinoid type-1 (CB) and type-2 (CB) receptors, showing only modest allosteric modulation of both end-points. CBD and CBDV are biosynthesized as optically highly pure (−)-enantiomers, and most bioactivity data refer to these forms. (+)-CBD and related analogues [(+)-cannabidiolic acid (CBDA), its esters, and (+)-CBDV] can be obtained by chemical synthesis, and we present evidence that the (+)- and (−)-enantiomers of CBD, CBDV and of a selection of derivatives of CBDA have distinct binding profiles and functional activity at the CB/CB receptors. Thus, with the single exception of the methyl ester of CBDA, all the (+)-enantiomers showed higher affinities than the (−)-isomers for both receptors, in particular for the CB receptors. The affinity of the (+)-enantiomers for both CB and CB receptors showed a marked dependence on the nature of the alkyl residue on the aromatic ring and the esterification pattern of CBDA. Potency was rarely in the low nM value for CB, but generally so for CB. Enantiomers showing low nM activity were further investigated for their intrinsic activity using GTPγS binding assays. This proved that (+)-CBD, (+)-CBDV and the methyl ester of (+)-CBDA are agonists at the CB receptor, with the β-hydroxyethyl ester of (+)-CBDA being an inverse agonist, and its β-hydroxypentyl ester behaving as an agonist at CB and an inverse agonist at CB. Finally, we assayed in vitro the anti-inflammatory and neuroprotective properties of three compounds [(+)-CBD, (+)-CBDV and (+)-CBDA methyl ester] strongly activating CB, showing their ability to reduce the production of proinflammatory factors and protecting neurons against their toxicity. Remarkably, these benefits were eliminated by the selective blockade of the CB receptor, highlighting its role as a (+)-CBD target. In summary, our data show that remarkable differences between (−)- and (+)-enantiomers of CBD, CBDV and related compounds exist in terms of CB/CB receptor binding profile and intrinsic activity. The observation that the natural (−)-enantiomers do not bind CB receptors suggests that their effects are associated with different targets., Authors want to thank the support by grants from MCINN “Programa Nacional de Biomedicina” (PID2021-128906OB-I00 to JF-R) with co- funding from the European Regional Development Funds (FEDER), “Instituto de Salud Carlos III” (CIBERNED, CB06/05/0089), Symrise AG, Holzminden, Germany, and VivaCell Biotechnology-Spain. These agencies had no further role in study design, the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.